Data / Form D filings / RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc.: Form D filings
RetinalGenix Technologies Inc., a biotechnology company in Apollo Beach, FL, filed 3 Form D notices with the SEC between 2021 and 2025. The latest, on February 11, 2025, reports $653,089 sold of a $5 million offering to 30 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 409 APOLLO BEACH BLVD, SUITE 6, Apollo Beach, FL, 33572
- Phone
- (415) 578-9583
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1836295
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 11, 2025 | Amendment | $5,000,000 | $653,089 | $4,346,911 | 30 | Jan 23, 2024 | sec.gov |
| Feb 9, 2024 | New notice | $4,650,000 | $4,650,000 | 17 | Jan 23, 2024 | sec.gov | |
| Jul 1, 2021 | New notice | $7,000,000 | $45,000 | $6,955,000 | 3 | Jun 4, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jerry Katzman | Executive Officer, Director | |
| Vinay Mehindru | Director | |
| Herbert Gould | Director |
Other biotechnology companies in Florida that filed recently
- AdhereBio LLC offering · Oct 26, 2026
- Ascoltare Holdings LLC $1.7 million · Oct 23, 2026
- Immorta Bio, Inc. $612,503 · Oct 16, 2026
- CURADEL SURGICAL INNOVATIONS, INC. $49.8 million · Oct 13, 2026
- BioStem Technologies, Inc. $3 million · Oct 9, 2026
- HCW Biologics Inc. $1.5 million · Oct 8, 2026
Every Form D from the week of Feb 10, 2025 · All recent filings in Florida · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what RetinalGenix Technologies Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.